国际口腔医学杂志 ›› 2020, Vol. 47 ›› Issue (1): 43-50.doi: 10.7518/gjkq.2020025

• 口腔黏膜专栏 • 上一篇    下一篇

口腔黏膜癌变过程中血清生化标志物的研究进展

董云梅,陶艳,周瑜()   

  1. 口腔疾病研究国家重点实验室 国家口腔疾病临床医学研究中心 四川大学华西口腔医院口腔黏膜病科 成都 610041
  • 收稿日期:2019-03-19 修回日期:2019-09-28 出版日期:2020-01-01 发布日期:2020-01-01
  • 通讯作者: 周瑜
  • 作者简介:董云梅,硕士,Email: 921520435@qq.com
  • 基金资助:
    国家自然科学基金(81771086);国家自然科学基金(81470747)

Research progress on serum biochemical substances associated with oral malignant transformation

Dong Yunmei,Tao Yan,Zhou Yu()   

  1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2019-03-19 Revised:2019-09-28 Online:2020-01-01 Published:2020-01-01
  • Contact: Yu Zhou
  • Supported by:
    This study was supported by National Natural Science Foundation of China(81771086);This study was supported by National Natural Science Foundation of China(81470747)

摘要:

口腔黏膜癌变是指口腔黏膜从正常状态经口腔潜在恶性疾患阶段发展为口腔鳞状细胞癌,直至远处转移的多步骤、多阶段、多基因改变的过程。该过程涉及多种血清生化标志物的变化,这些动态变化对于病情的进展具有重要的提示作用,对临床有着深远的意义。本文将与口腔黏膜癌变过程相关的血清生物标志物的研究现状作一综述。

关键词: 口腔黏膜癌变, 口腔潜在恶性疾患, 口腔鳞状细胞癌, 血清生化标志物

中图分类号: 

  • R781.5[文献标志码]A[doi]10.7518/gjkq.2020025
[1] George A, Sreenivasan BS, Sunil S , et al. Potentially malignant disorders of oral cavity[J]. Oral Maxillofac Pathol J, 2011,2(1):95-100.
[2] 石佳鸿, 周红梅 . 口腔潜在恶性病变的无创筛查及管理[J]. 中国实用口腔科杂志, 2015,8(12):705-708.
Shi JH, Zhou HM . Noninvasive screening and intervention of oral potential malignant disorders[J]. Chin J Pract Stomatol, 2015,8(12):705-708.
[3] 李晨曦, 施琳俊, 唐国瑶 . 无创筛查技术早期诊断口腔潜在恶性病患癌变的研究进展[J]. 临床口腔医学杂志, 2017,33(6):381-383.
Li CX, Shi LJ, Tang GY . Advances in non-invasive screening techniques for early diagnosis of canceration in oral potential malignant diseases[J]. J Clin Stomatol, 2017,33(6):381-383.
[4] Scully C . Serum β2 microglobulin in oral malignancy and premalignancy[J]. J Oral Pathol Med, 1981,10(5):354-357.
[5] Singh AP, Kumar N, Raju MS , et al. Estimation of serum β2-microglobulin in potentially malignant disorders and squamous cell carcinoma of the oral cavity: a clinicopathological study[J]. Dent Res J (Isfahan), 2014,11(1):109-113.
[6] Kadam CY, Katkam RV, Suryakar AN , et al. Biochemical markers in oral cancer[J]. Biomed Res, 2011,22(1):76-80.
[7] Chen CH, Su CY, Chien CY , et al. Overexpression of β2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion[J]. Br J Cancer, 2008,99(9):1453-1461.
[8] Bouquot J, Suarez P, Nadarajah V . Oral precancer and early detection in the dental office- review of new technologies[J]. J Implant Advanced Clin Dent, 2010,2(3):47-63.
[9] Saddiwal R, Hebbale M, Sane VD , et al. Estimation of serum beta 2-microglobulin levels in individuals exposed to carcinogens: clinical study in Indian population[J]. J Maxillofac Oral Surg, 2017,16(1):53-57.
[10] Sanjay RB, Madhavi RB, Shyam NDVN . Tumor markers in oral neoplasia[J]. Indian J Dent Adv, 2010,2(1):103-114.
[11] Rhodus NL.Oralcancer and precancer: improving outcomes[J]. Compend Contin Educ Dent, 2009, 30(8):486-488, 490-494, 496-498, 504, 520.
[12] Silvia CR, Vasudevan DM, Prabhu KS . Alteration of serum beta 2-microglobulin in oral carcinoma[J]. Indian J Clin Biochem, 2002,17(2):104-107.
[13] Mazher N, Iqbal Z, Aslam N , et al. Beta-2-microglobulin as a marker of extent of disease in non-Hodgkin lymphoma[J]. Biomed, 2010,26(4):1-4.
[14] Nisman B, Lafair J, Heching N , et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma[J]. Cancer, 1998,82(10):1850-1859.
[15] Zhong LP, Zhu HG, Zhang CP , et al. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma[J]. Int J Oral Maxillofac Surg, 2007,36(3):230-234.
[16] Rajkumar K, Ramya R, Nandhini G , et al. Salivary and serum level of CYFRA 21-1 in oral precancer and oral squamous cell carcinoma[J]. Oral Dis, 2015,21(1):90-96.
[17] Hamakawa H, Bao Y, Takarada M , et al. Cytokeratin expression in squamous cell carcinoma of the lung and oral cavity: an immunohistochemical study with possible clinical relevance[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1998,85(4):438-443.
[18] Feng XY, Li JH, Li JZ , et al. Serum SCCA, Cyfra 21-1, EGFR and Cyclin D1 levels in patients with oral squamous cell carcinoma[J]. Int J Biol Markers, 2010,25(2):93-98.
[19] Barnett EV . Circulating immune complexes: their immunochemistry, detection, and importance[J]. Ann Intern Med, 1979,91(3):430.
[20] Taneja N, Bathi R, Deka AC , et al. Evaluation of circulating immune complexes and serum immunoglobulins in oral cancer patients - A follow up study[J]. Indian J Dent Res, 2010,21(1):10.
[21] Lichtenstein A, Zighelboim J, Dorey F , et al. Comparison of immune derangements in patients with different malignancies[J]. Cancer, 1980,45(8):2090-2095.
[22] Scully C . Immunological abnormalities in oral carcinoma and oral keratosis[J]. J Maxillofac Surg, 1982,10:113-115.
[23] Maheswari H, Eswaran MA, Srividhya S , et al. Estimation of circulating immune complexes in patients with oral leukoplakia and oral submucous fibrosis: a case control study[J]. J Clin Diagn Res, 2014,8(1):224-227.
[24] Scully C, Barkas T, Boyle P , et al. Circulating immune complexes detected by binding of radiolabelled protein A in patients with oral cancer and oral premalignant lesions[J]. J Clin Lab Immunol, 1982,8(2):113-115.
[25] Tiwari R, David CM, Mahesh DR , et al. Assessment of serum copper, iron and immune complexes in potentially malignant disorders and oral cancer[J]. Braz Oral Res, 2016,30(1):e101.
[26] Wang J, You JL, Wang LK , et al. PTMA, a new identified autoantigen for oral submucous fibrosis, regulates oral submucous fibroblast proliferation and extracellular matrix[J]. Oncotarget, 2017,8(43):74806-74819.
[27] Jayadeep A, Raveendran Pillai K, Kannan S , et al. Serum levels of copper, zinc, iron and ceruplasmin in oral leukoplakia and squamous cell carcinoma[J]. J Exp Clin Cancer Res, 1997,16(3):295-300.
[28] Khanna SS, Karjodkar FR . Circulating immune complexes and trace elements (copper, iron and selenium) as markers in oral precancer and cancer: a randomised, controlled clinical trial[J]. Head Face Med, 2006,2:33.
[29] Shah PH, Venkatesh R, More CB . Determination of role of ceruloplasmin in oral potentially malignant disorders and oral malignancy—a cross-sectional study[J]. Oral Dis, 2017,23(8):1066-1071.
[30] Hosthor SS, Mahesh P, Priya SA , et al. Quantitative analysis of serum levels of trace elements in patients with oral submucous fibrosis and oral squamous cell carcinoma: a randomized cross-sectional study[J]. J Oral Maxillofac Pathol, 2014,18(1):46-51.
[31] Ramanathan K . Oral submucous fibrosis—an alterna-tive hypojournal as to its causes[J]. Med J Malaysia, 1981,36(4):243-245.
[32] Aziz NZ, Arathi K, Prasad BG , et al. Evaluation of magnesium levels in blood and saliva of oral squamous cell carcinoma and potentially malignant disorders by xylidyl blue method[J]. J Oral Maxillofac Pathol, 2018,22(1):147.
[33] Wickramasinghe S, Medrano JF . Primer on genes encoding enzymes in sialic acid metabolism in mammals[J]. Biochimie, 2011,93(10):1641-1646.
[34] Dhakar N, Astekar M, Jain M , et al. Total sialic acid, total protein and total sugar levels in serum and saliva of oral squamous cell carcinoma patients: a case control study[J]. Dent Res J (Isfahan), 2013,10(3):343-347.
[35] Rajpura KB, Patel PS, Chawda JG , et al. Clinical significance of total and lipid bound sialic acid levels in oral pre-cancerous conditions and oral cancer[J]. J Oral Pathol Med, 2005,34(5):263-267.
[36] Krishnan K , Balasundaram S. Evaluation of total and lipid bound sialic acid in serum in oral leukoplakia [J].J Clin Diagn Res, 2017,11(3):ZC25-ZC27.
[37] Bose KS, Gokhale PV, Dwivedi S , et al. Quantitative evaluation and correlation of serum glycoconjugates: protein bound hexoses, sialic acid and fucose in leukoplakia, oral sub mucous fibrosis and oral cancer[J]. J Nat Sci Biol Med, 2013,4(1):122-125.
[38] Sawhney H, Kumar CA . Correlation of serum bio-markers (TSA & LSA) and epithelial dysplasia in early diagnosis of oral precancer and oral cancer[J]. Cancer Biomark, 2011,10(1):43-49.
[39] Parwani R, Parwani S . Quantitative evaluation of serum fucose in oral squamous cell carcinoma patients[J]. J Can Res Ther, 2011,7(2):143.
[40] Rai NP, Anekar J, Shivaraja Shankara YM , et al. Comparison of serum fucose levels in leukoplakia and oral cancer patients[J]. Asian Pac J Cancer Prev, 2015,16(17):7497-7500.
[41] Chinnannavar SN, Ashok L, Vidya KC , et al. Eva-luation of serum sialic acid, fucose levels and their ratio in oral squamous cell carcinoma[J]. J Int Soc Prev Community Dent, 2015,5(6):446-450.
[42] Piva MR, DE Souza LB, Martins-Filho PR , et al. Role of inflammation in oral carcinogenesis (Part Ⅱ): CD8, FOXP3, TNF-α, TGF-β and NF-κB expression[J]. Oncol Lett, 2013,5(6):1909-1914.
[43] Chang KP, Kao HK, Wu CC , et al. Pretreatment interleukin-6 serum levels are associated with patient survival for oral cavity squamous cell carcinoma[J]. Otolaryngol Head Neck Surg, 2013,148(5):786-791.
[44] Chen Z, Malhotra PS, Thomas GR , et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer[J]. Clin Cancer Res, 1999,5(6):1369-1379.
[45] Kaur J, Jacobs R . Proinflammatory cytokine levels in oral lichen planus, oral leukoplakia, and oral submucous fibrosis[J]. J Korean Assoc Oral Maxillofac Surg, 2015,41(4):171-175.
[46] Aggarwal BB, Kumar A, Bharti AC . Anticancer potential of curcumin: preclinical and clinical studies[J]. Anticancer Res, 2003,23(1A):363-398.
[47] Pepys MB, Hirschfield GM . C-reactive protein: a critical update[J]. J Clin Invest, 2003,111(12):1805-1812.
[48] Kumar K, Kantheti LP, Reddy BV , et al. Quantitative analysis of C-reactive protein in potentially malignant disorders: a pilot study[J]. J Orofac Sci, 2015,7(1):3.
[49] Bhattacharjee K, Girish HC, Sanjay M , et al. Comparison of serum C-reactive protein level in oral potentially malignant disorders and in healthy individuals[J]. Res J Pharmaceutic Biolog Chemic Sci, 2016,7(2):1285-1290.
[50] Chang PY, Kuo YB, Wu TL , et al. Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer[J]. Clin Chem Lab Med, 2013,51(6):1291-1300.
[51] Patel BP, Shah SV, Shukla SN , et al. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer[J]. Head Neck, 2007,29(6):564-572.
[52] Lotfi A, Mohammadi G, Tavassoli A , et al. Serum levels of MMP9 and MMP2 in patients with oral squamous cell carcinoma[J]. Asian Pac J Cancer Prev, 2015,16(4):1327-1330.
[53] Kayden HJ, Chow CK, Bjornson LK . Spectrophotometric method for determination of tocopherol in red blood cells[J]. J Lipid Res, 1973,14(5):533-540.
[54] Lawal AO, Kolude B, Adeyemi BF , et al. Serum antioxidant vitamins and the risk of oral cancer in patients seen at a tertiary institution in Nigeria[J]. Niger J Clin Pract, 2012,15(1):30-33.
[55] Bhat S, Babu S, Bhat S , et al. Status of serum and salivary ascorbic acid in oral potentially malignant disorders and oral cancer[J]. Indian J Med Paediatr Oncol, 2017,38(3):306.
[56] Yu T, Liu K, Wu Y , et al. MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway[J]. Oncogene, 2014,33(42):5017-5027.
[57] Sun LG, Liu L, Fu HH , et al. Association of decreased expression of serum miR-9 with poor prognosis of oral squamous cell carcinoma patients[J]. Med Sci Monit, 2016,22:289-294.
[58] El-Sakka H, Kujan O, Farah CS . Assessing miRNAs profile expression as a risk stratification biomarker in oral potentially malignant disorders: a systematic review[J]. Oral Oncol, 2018,77:57-82.
[1] 周金阔,张晋弘,史晓晶,刘广顺,姜磊,刘倩峰. 长链非编码RNA小核仁RNA宿主基因22调控微小RNA-27b-3p对口腔鳞状细胞癌细胞增殖、侵袭和迁移的影响[J]. 国际口腔医学杂志, 2024, 51(1): 52-59.
[2] 李立恒,王蕊,王晓明,张智轶,张璇,安峰,王芹,张凡. 环状RNA hsa_circ_0085576调控微小RNA-498/B细胞特异性莫洛尼鼠白血病病毒整合位点1轴对口腔鳞状细胞癌细胞迁移和侵袭的影响[J]. 国际口腔医学杂志, 2024, 51(1): 60-67.
[3] 吴佳敏,夏斌,杨禾丰,许彪. 癌相关成纤维细胞在口腔鳞状细胞癌微环境中作用的研究进展[J]. 国际口腔医学杂志, 2023, 50(6): 711-717.
[4] 柳江龙, 买买提吐逊·吐尔地. 超声造影在口腔鳞状细胞癌颈部转移性淋巴结诊断中的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 514-520.
[5] 盛南宁,王珏,南欣荣. 性别决定基因盒9在口腔鳞状细胞癌作用机制和治疗中的研究进展[J]. 国际口腔医学杂志, 2023, 50(3): 314-320.
[6] 李潭,梁新华. 盘状蛋白结构域受体1在调控恶性肿瘤进展和治疗中的作用[J]. 国际口腔医学杂志, 2023, 50(2): 230-236.
[7] 赵卓平,辛鹏飞,高阳,张彩凤,张宽收,刘青梅. 光热治疗在口腔鳞状细胞癌治疗中的研究进展[J]. 国际口腔医学杂志, 2022, 49(4): 462-470.
[8] 江涵,神应强,陈谦明. 毒蕈碱受体通过Yes相关蛋白信号对口腔鳞状细胞癌生物学行为的实验研究[J]. 国际口腔医学杂志, 2022, 49(2): 138-143.
[9] 蒋宇磊,夏斌,饶南荃,杨禾丰,许彪. 外泌体在口腔鳞状细胞癌恶性进展及诊疗应用的研究[J]. 国际口腔医学杂志, 2021, 48(6): 711-717.
[10] 甘建国,高攀,王晓毅. 循环肿瘤细胞与口腔鳞状细胞癌相关性的研究进展[J]. 国际口腔医学杂志, 2021, 48(2): 205-212.
[11] 黄俊文,乔洁,梅子,陈茁,李杨,乔彬. 脂多糖结合蛋白在口腔鳞状细胞癌中的表达及其临床意义[J]. 国际口腔医学杂志, 2021, 48(1): 50-57.
[12] 何宇晴,但红霞,陈谦明. 光动力疗法在口腔黏膜癌变防治中的应用[J]. 国际口腔医学杂志, 2020, 47(6): 669-676.
[13] 郝福,宁毅,孙睿,郑晓旭. 口腔鳞状细胞癌中转化因子2β的表达及潜在的临床意义[J]. 国际口腔医学杂志, 2020, 47(2): 159-165.
[14] 薛伶俐,李雅冬. 经首次根治性手术治疗口腔鳞状细胞癌患者的生存相关影响因素分析[J]. 国际口腔医学杂志, 2020, 47(2): 166-174.
[15] 陈宏丽,杨敬,尹刚,李皓缘,乔燕. 锌指蛋白32在口腔鳞状细胞癌中的表达意义及对口腔鳞状细胞癌干细胞的影响[J]. 国际口腔医学杂志, 2019, 46(6): 631-639.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 张新春. 桩冠修复与无髓牙的保护[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 王昆润. 长期单侧鼻呼吸对头颅发育有不利影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[3] 彭国光. 颈淋巴清扫术中颈交感神经干的解剖变异[J]. 国际口腔医学杂志, 1999, 26(05): .
[4] 杨凯. 淋巴化疗的药物运载系统及其应用现状[J]. 国际口腔医学杂志, 1999, 26(05): .
[5] 康非吾. 种植义齿下部结构生物力学研究进展[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 柴枫. 可摘局部义齿用Co-Cr合金的激光焊接[J]. 国际口腔医学杂志, 1999, 26(04): .
[7] 孟姝,吴亚菲,杨禾. 伴放线放线杆菌产生的细胞致死膨胀毒素及其与牙周病的关系[J]. 国际口腔医学杂志, 2005, 32(06): 458 -460 .
[8] 费晓露,丁一,徐屹. 牙周可疑致病菌对口腔黏膜上皮的粘附和侵入[J]. 国际口腔医学杂志, 2005, 32(06): 452 -454 .
[9] 赵兴福,黄晓晶. 变形链球菌蛋白组学研究进展[J]. 国际口腔医学杂志, 2008, 35(S1): .
[10] 庞莉苹,姚江武. 抛光和上釉对陶瓷表面粗糙度、挠曲强度及磨损性能的影响[J]. 国际口腔医学杂志, 2008, 35(S1): .